Date de Début
01
Jan 2021
Statut
Ongoing
Membres
5
Structures
5
Publications
3
Financements
Références
-
2023Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma., Front Oncol 2023 ; 13(): 1110916.
-
2022The Sec61 translocon is a therapeutic vulnerability in multiple myeloma., EMBO Mol Med 2022 03; 14(3): e14740.
-
2018Proteomics reveals scope of mycolactone-mediated Sec61 blockade and distinctive stress signature, Mol. Cell Proteomics 2018 Jun;.